Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2014 - 2026)
Lineage Cell Therapeutics (LCTX) reported EPS (Weighted Average and Diluted) of -$0.03 for Q1 2026, down 50.0% on a YoY basis from -$0.06 in Q1 2025, and down 142.7% quarter-over-quarter from $0.07 in Q4 2025.
Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported EPS (Weighted Average and Diluted) for 13 years, with the latest figure at -$0.03 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 50.0% year-over-year to -$0.03; the trailing twelve-month figure through Mar 2026 stood at -$0.29 (down 262.5% YoY), and the FY2025 full-year result was -$0.28, down 211.11% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.03, down from $0.07 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.07 in Q4 2025, with the low at -$0.13 in Q2 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.04 across 5 years, with a median of -$0.03 in 2022.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 802.56% in 2025 against a maximum downside of 550.0% in 2025.
- Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.03 in 2022, then changed by 0.0% to -$0.03 in 2023, then surged by 66.67% to -$0.01 in 2024, then jumped by 802.56% to $0.07 in 2025, then slumped by 142.7% to -$0.03 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.03 (Q1 2026), $0.07 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.13 |
| Mar 31, 2025 | -0.02 |
| Dec 31, 2024 | -0.01 |
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | -0.03 |
| Mar 31, 2024 | -0.04 |
| Dec 31, 2023 | -0.03 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.03 |
| Mar 31, 2023 | -0.03 |
| Dec 31, 2022 | -0.03 |
| Sep 30, 2022 | -0.04 |
| Jun 30, 2022 | -0.04 |
| Mar 31, 2022 | -0.04 |
| Sep 30, 2021 | -0.05 |
| Jun 30, 2021 | -0.03 |
| Mar 31, 2021 | -0.01 |